These findings strongly suggest an association between AIMP1/2/3 genes and angiogenesis pathways across cancers, providing rationale for investigating the role of AIMPs in antiangiogenesis treatment response in GBM and LGG due to AIMPs’ role in central nervous system functions and the increased vascularity in these tumors. The gene discussed is AIMP1; the disease is cancer.